Validation regression slope
1.1 slope
- EndpointRegression of Rapid RV/LV measurement against expert ground truth
- Population124 CTPA cases with ground truth established by three experts
- Tested versionRapid RV/LV configuration submitted in K223396
FDA-cleared profile
iSchema View Inc. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Adjunctive measurement of the RV/LV ratio as a clinical metric used by medical professionals to quantify severity of right-heart strain in adults evaluated with CTPA; the annotated measurements support, but do not replace, clinical assessment.
Evidence takeaway. Evidence from the reviewed source record: Final FDA validation included 124 CTPA cases with ground truth established by three experts. The reported average slope was 1.1, average intercept -0.2, Bland-Altman mean bias 0.023 and mean absolute error 3.8 mm; the source text reports the associated confidence intervals, including malformed intercept-CI formatting.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
The FDA endpoints are continuous ventricular measurements and agreement statistics, not disease-detection sensitivity.
The FDA endpoints are continuous ventricular measurements and agreement statistics, not disease-detection specificity.
1.1 slope
-0.2 ratio units
0.023 RV/LV ratio units
3.8 mm
K223396
The FDA source prints a malformed confidence-interval expression for the intercept; the reported intercept value is preserved without reconstructing or recalculating that interval.
K223396
The source wording for the development split is retained; this dataset is not used as a substitute for the 124-case final validation.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
The exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Adult volumetric CTPA acquisitions provided as DICOM images; the FDA comparison identifies non-gated CT angiography images as the input requirement.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV
Source context, not route validation: The module operates within the integrated Rapid Platform, accepts CTPA DICOM, uses a command-line interface and provides reports, DICOM Secondary Capture and JSON quantitative output for downstream review or integration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA summary establishes Rapid Platform and command-line integration but does not establish the current exact K223396 hosting model.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-07 ·
Source context, not route validation: Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV
Unresolved route: Annotated images with the ventricular measurement locations, quantitative maximal right- and left-ventricular diameters, the RV/LV ratio, a visual color-overlay result, a text report and a JSON text file containing quantitative measurement results; DICOM Secondary Capture is also described.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-07 · FDA 510(k) K223396: Rapid RV/LV
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.
The cleared module operates within the integrated Rapid Platform, accepts CTPA DICOM through a command-line interface and produces annotated images, reports, DICOM Secondary Capture and JSON quantitative measurement results.
exact submission · checked 2026-09-07RapidAI's current PE page lists Rapid PE RV/LV as a PE solution and describes bringing AI results, source imaging and clinical data into one platform, with EHR integration, care-team communication and analytics described at the family level.
product family · checked 2026-09-07The current family page does not establish exact K223396 release, hosting, connector, price or performance terms.
RapidAI's current security one-pager lists encryption at rest and in transit, role-based access control, monitoring/logging, secure development practices and a vendor-stated compliance framework for its platform portfolio.
vendor wide · checked 2026-09-07This is vendor-supplied portfolio context and is not independent confirmation of exact K223396 controls or contractual scope.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored candidate metadata was screened. The broad Rapid RV/LV query returned 20 PubMed identifiers without exact K223396 linkage established in metadata; no full paper was reviewed and no candidate is promoted as product evidence. The current discovery snapshot contains 20 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor technical documentation, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price or quote for the exact K223396 configuration was reviewed.
Bounded web search on 2026-10-26 (query: "Rapid CTA 360 RapidAI reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. RapidAI's reimbursement page lists NTAP for Rapid LVO (FY2021-2022 rules); it does not name this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
The exact FDA summary establishes Rapid Platform and command-line integration but does not establish the current exact K223396 hosting model.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
9 sources - 3 history items
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation
Scope: regulatoryIdentity, modalityContext
Scope: purpose, modality, intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamily, clinicalWorkflow, implementationCapabilities
Scope: vendorWideSecurity, deployment, implementationCapabilities
Scope: security, monitoring
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Keya Medical Technology Co., Ltd.
Authorized purpose: Coronary plaque and stenosis quantification from CCTA
Canon Medical Informatics, Inc.
Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.
Circle Cardiovascular Imaging, Inc.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Careverse Technology Pte. Ltd.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history